Sulpirida

Quick links to important sections

Sulpirida

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulpirida

Sulpirida is a pharmaceutical preparation whose primary function is to help stabilize mental and emotional processes through its sole active component, Sulpiride.


Quick Facts

Property Description
Active ingredient Sulpiride (INN)
Pharmacological class Atypical Antipsychotic, Benzamide Derivative
Forms Tablet, Hard Capsule, Oral Liquid, Injectable Solution
Common Use Stabilization of psychological states and mental function
Origin Synthetic organic compound

Classification and Origin: What Type of Medicine is Sulpirida?

The active compound, Sulpiride, is a synthetic organic compound derived from the substituted benzamide chemical family. Pharmacologically, Sulpiride is defined as an atypical antipsychotic or neuroleptic, recognized for its selective influence on the central nervous system. This agent is classified within the Benzamide subclass. Its unique property is its dual, dose-dependent mechanism, a feature clinically recognized to offer a broader spectrum of action compared to older, less selective agents. As a single-active-ingredient product, Sulpirida's effect relies entirely on the nuanced activity of this one substance.


Composition and Available Forms

Sulpirida is manufactured with the active substance Sulpiride, which chemically exists as a racemic mixture of two enantiomers. The medicine is prepared for both oral and intramuscular delivery, a characteristic that offers flexibility in patient management; for instance, the injectable solution is often reserved for acute needs. Dosage forms include solid tablets and hard capsules, alongside oral liquid medicine. Various delivery forms are available to ensure flexibility in treatment regimens.


Core Action and General Purpose

The general purpose of Sulpirida is to regulate neurochemical imbalances that contribute to psychological distress, primarily by acting as a modulator of the dopaminergic system. The core action, achieved by influencing dopamine receptors, helps to regulate excessive or disorganized signaling within the brain. This action is designed to promote a more orderly pattern of neurotransmission, contributing to the essential function of psychological equilibrium and better emotional regulation. For example, it is typically used in situations where there is a clear need to stabilize thought patterns.

Regulatory References

  1. EMA Human Medicines
  2. National registers of authorised medicines (EMA)

What side effects are possible with Sulpirida?

Possible side effects and safety information

The safety profile of Sulpirida (Sulpiride) is officially documented across several categories, classified by frequency and impact on physiological systems according to government regulatory standards.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common (Affects le 1 in 10) Hyperprolactinaemia, Sedation or Drowsiness, Insomnia, Extrapyramidal disorder (e.g., tremor, stiffness), Weight gain, Galactorrhoea (abnormal milk production).
Uncommon (Affects le 1 in 100) Leukopenia (decreased white blood cells), Orthostatic hypotension, Dystonia, Amenorrhoea (absence of menstrual periods).
Rare (Affects le 1 in 1,000) Ventricular arrhythmia, Oculogyric crisis.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights serious but generally rare adverse events, including the potentially life-threatening Neuroleptic Malignant Syndrome (NMS) and severe heart rhythm disturbances such as Torsade de pointes, which is linked to QT interval prolongation. Other documented serious events are Venous Thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, and severe blood dyscrasias like Agranulocytosis.

Official safety constraints note that use is generally restricted in individuals with diagnosed or suspected prolactin-dependent tumors. Furthermore, specific population-specific safety considerations are documented, including an increased risk of death and cerebrovascular events in elderly patients with dementia-related psychosis. Time-related patterns include extrapyramidal symptoms often appearing early in treatment, whereas tardive dyskinesia is typically associated with prolonged administration.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Sulpirida may present as an exaggeration of its known pharmacological effects. While cases of overdose have been survived even with very high single doses (up to 16 grams), the potential for severe complications requires immediate attention.

Documented Overdose Manifestations

Symptoms following an overdose predominantly affect the central nervous and cardiovascular systems, including:

  • Central Nervous System (CNS) Effects: Over-sedation, progressing to a reduced level of consciousness or coma, agitation, and hallucinations. Severe cases may also present with convulsions.
  • Movement Disorders: Severe extrapyramidal signs such as dystonic crises (e.g., spastic movements of the neck or eyes, protrusion of the tongue, jaw lock), and marked muscle rigidity.
  • Cardiovascular Risks: Severe arrhythmias are the most critical risk, including QTc interval prolongation and potentially life-threatening conditions like Torsades de pointes and cardiac arrest. Other circulatory effects include low blood pressure (hypotension) and fast, irregular heartbeats.

When Immediate Medical Help is Required

All patients with a suspected Sulpirida overdose should receive immediate emergency medical attention and be transported to a hospital. This is due to the inherent risk of severe and potentially fatal cardiac arrhythmias. The official advice requires continuous, close monitoring for signs of QTc prolongation and severe heart rhythm disturbances. If severe symptoms such as loss of consciousness, uncontrolled muscle spasms, or breathing difficulties occur, contact emergency services immediately.

Therapeutic Uses of Sulpirida

What Sulpirida Treats: Main Uses and Benefits

Sulpirida is used to provide symptomatic support across several therapeutic domains involving heightened patient distress. It is applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. Its application includes therapeutic domains where additional symptomatic support is needed in major psychiatric and specific medical conditions.

It is commonly used across conditions presenting with acute episodes, such as Schizophrenia and certain major depressive disorders. It is also relevant for easing symptoms that interfere with daily comfort, like vertigo (dizziness) or episodes of agitation. In these scenarios, the medication helps address symptom clusters that create noticeable functional strain.

“The goal is to provide supportive relief when symptoms interfere with routine activities and help maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Relief for Disruption

Symptom Type Example Manifestation Benefit
Thought Disorder Delusions, Hallucinations Supports easier coping with symptom fluctuations.
Mood/Drive Deficit Apathy, Psychomotor Slowness Contributes to improved day-to-day comfort.
Balance Disturbance Severe Dizziness Assists with maintaining functional stability.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Sulpirida

Official regulatory documents define strict population rules governing the use of Sulpirida (Sulpiride).

Classification Population Status
Absolute Contraindication Patients with Phaeochromocytoma, Acute Porphyria, or Prolactin-dependent tumours (e.g., breast cancer, pituitary adenomas). Must Not Use
Patients concurrently receiving Levodopa or other dopaminergic anti-Parkinsonian agents. Must Not Use
Age Restriction Children under 14 years of age. Not Recommended
Physiological Status Pregnant women and breastfeeding women. Not Recommended

Eligibility is further restricted for specific medical conditions. Use requires particular caution and monitoring in elderly patients and individuals with renal impairment, as Sulpiride is primarily eliminated by the kidneys. Patients with a history of epilepsy or risk factors for QT prolongation (a heart rhythm concern), stroke, or Venous Thromboembolism (VTE) must also be monitored, as defined by official regulatory labeling.

What should I know about interactions with other medicines?

The official interaction profile of Sulpirida (Sulpiride) is defined by its functional effects on the central and cardiovascular systems, as well as specific constraints on gastrointestinal co-administration.

Official Interaction Statements

Classification Interacting Agents Official Interaction Outcome Timing Rule
Contraindicated Combination Levodopa and other Dopaminergic Agonists (e.g., Ropinirole) Reciprocal antagonism of effects [SmPC]. None
Association Not Recommended QT Prolonging Drugs (e.g., Amiodarone, Sotalol) & Bradycardia-inducing Medicines (e.g., Diltiazem, Verapamil) Enhanced risk of serious ventricular arrhythmias (e.g., Torsade de Pointes) [SmPC]. None
CNS Additive Effects Alcohol and CNS Depressants (e.g., Sedative H1 Antihistamines, Barbiturates) Enhanced sedative effect and possibility of enhanced postural hypotension [SmPC]. Consumption must be avoided
Absorption Interference Antacids or Sucralfate Decreased absorption of Sulpirida, resulting in reduced exposure [SmPC]. Must be administered two hours before Antacids/Sucralfate
Increased Risk Lithium and Metoclopramide Increased risk of extrapyramidal adverse reactions [Regulatory Source]. None

Contextual Constraints

Regulatory documentation classifies the interactions as primarily pharmacodynamic (functional or additive effects) and pharmacokinetic (absorption kinetics). The official profile specifically notes that Sulpirida neither inhibits nor stimulates the Cytochrome P450 enzyme family, which means it is not expected to cause clinically significant CYP-mediated interactions with other medicines. The use of alcoholic beverages and medicines containing alcohol is strictly restricted due to potentiation of the CNS depressant effect.

Mechanism of Action

Selective Dopamine Receptor Modulation

Sulpirida's core mechanism involves acting as a selective antagonist (blocker) primarily on the mathbfD2 and mathbfD3 subtypes of the dopamine receptor within the central nervous system. By occupying these receptor sites on the surface of nerve cells, the drug prevents the binding of endogenous dopamine, thus modulating the flow of dopamine-related signals. This antagonism alters subsequent molecular signaling cascades within specific neural circuits.


Neurotransmitter Signal Transmission

This modification of D2 signaling alters the physiological response to heightened or reduced dopamine activity, resulting in altered electrical and chemical dynamics within key pathways associated with cognitive and emotional processing. At high concentrations, the drug may also have a marginal influence on certain serotonin receptors.


Impact on Neuroendocrine Pathways

Beyond its central effects, Sulpirida's D2 receptor antagonism extends to the pituitary gland, a component of the neuroendocrine system. This action removes the natural inhibitory control exerted by dopamine on prolactin release, leading directly to its increased secretion, which is a physiological consequence of the drug's mechanism on the endocrine pathway.

Dosage and Administration Information

Sulpirida is administered primarily through the oral route using available forms such as tablets, hard capsules, or liquid solution. An injectable solution is also available, which is typically reserved for intramuscular administration in acute settings.

Administration Scope

The medicine is generally taken in two divided doses daily, often scheduled for the morning and early evening, though some low-dose regimens may require three daily administrations. Oral tablets must be swallowed whole with water as a key instruction for proper use. There is a wide therapeutic range for this agent; the daily dose typically starts at 400 mg and may be increased up to a maximum recommended dose of 2400 mg. The exact dosage is adjusted by the treating specialist based on the patient’s response.

Population-Specific Use

Usage protocols mandate specific modifications for certain populations. In older adults, while the therapeutic range may be similar to that of younger adults, treatment usually starts at a lower initial dose (e.g., 50 mg to 100 mg twice daily) followed by cautious titration. Patients with renal impairment must have their dose reduced or the interval between administrations increased, with specific adjustments tied to creatinine clearance. Furthermore, the use of this medicine is generally not recommended in children under 14 years of age due to insufficient data.

Procedural Instructions

If a scheduled dose is missed, a double dose should not be taken; the patient should either take the missed dose as soon as possible or skip it if it is nearly time for the next scheduled dose. Initiation of treatment for major conditions requires supervision by a specialist.

Recent Clinical Evidence

Sulpiride is an antipsychotic medication of the benzamide class that has been subject to clinical study for several decades. It is available in many countries globally but is not currently approved for use in the United States or Canada.

Clinical Applications and Research Focus

Clinical trials and evidence summaries suggest sulpiride is primarily investigated for its effects in two main areas:

  • Schizophrenia: Sulpiride is indicated for the treatment of acute and chronic symptoms of schizophrenia in various international markets. Research comparing sulpiride to other antipsychotic agents has explored its effectiveness in managing both positive symptoms (such as hallucinations and delusions) and negative symptoms (like social withdrawal or blunted affect). Some data indicate a similar spectrum of activity to certain older antipsychotics.
  • Major Depressive Disorder (MDD): The medication has also been studied and approved for use in MDD in some countries, notably Japan. Low-dose regimens have been associated with a potential effect on depressive symptoms and may be utilized in patients who do not respond adequately to standard antidepressants alone. Controlled studies have compared its effects to placebo in depressive disorders.

Other Investigated Uses

Beyond its primary applications, sulpiride has been explored in clinical research for other conditions, demonstrating the breadth of its potential action:

  • Vertigo: The agent is indicated for the treatment of vertigo in some countries.
  • Anti-emetic Properties: Trials have investigated the use of sulpiride as an anti-nausea and anti-vomiting (anti-emetic) agent in various medical contexts.
  • Menopausal Symptoms: Early research has also explored its potential in helping to reduce hot flashes associated with menopausal syndrome.

Tolerability and Safety Profile

Overall safety data from long-term clinical experience suggest sulpiride is generally well-tolerated compared to some older-generation antipsychotics, with a potentially lower risk of certain neurological side effects. However, like all drugs, it is associated with a range of possible adverse effects. A notable finding is the frequent elevation of the hormone prolactin, which can lead to related effects in both men and women. The potential for drug-drug interactions, particularly with other agents affecting the central nervous system or heart rhythm, is monitored in clinical practice.

Frequently Asked Questions (FAQ)

Common questions about Sulpirida (FAQ)

Q: Is Sulpirida considered a type of antidepressant?

Official pharmacological information states that Sulpirida is classified as an atypical antipsychotic medicine. However, it is also noted to possess antidepressant properties and is approved in some international markets for the treatment of Major Depressive Disorder. Its primary classification relates to how it modulates the dopaminergic system in the brain.

Q: Are there any common over-the-counter medicines that interact with Sulpirida?

Yes, official interaction warnings mention certain common over-the-counter products. Antacids and Sucralfate can reduce the absorption of Sulpirida, meaning they must be taken at least two hours before it. Warnings also apply to sedative antihistamines due to a possible enhanced sedative effect.

Q: Is Sulpirida generally safe to use for older adults?

Regulatory guidelines specify modifications for use in older adults, where treatment is typically started at a lower dose. The patient's renal function must also be monitored. Official warnings note an increased risk of stroke and death in elderly patients diagnosed with dementia-related psychosis.

Q: What are some of the most common reasons someone might be asked to stop using Sulpirida?

The medicine is subject to regulatory constraints requiring discontinuation if a severe reaction occurs, such as Neuroleptic Malignant Syndrome (NMS). Furthermore, the medicine must not be continued if a condition representing an absolute contraindication, like a prolactin-dependent tumor, is present. Common adverse effects, such as significant weight gain or high levels of prolactin, may also lead a specialist to recommend a change in treatment.

Q: Are there any foods or vitamins that should be avoided while on Sulpirida?

Official regulatory documents do not list specific foods or vitamins that must be avoided. However, the medicine must be taken separately from Antacids or Sucralfate because they can reduce its absorption. Due to the enhanced sedative effect on the central nervous system, official regulatory information states that alcoholic beverages are subject to a strict restriction while using this medicine.

Q: Is Sulpirida known to cause changes in mood or personality?

The core function of Sulpirida is to modulate brain signaling to promote the stabilization of thought patterns and emotional processes. However, official safety information lists common side effects like sedation, drowsiness, and insomnia, which can naturally affect an individual's mental state.

Q: Is it normal to feel a bit dizzy when first starting Sulpirida?

Official information reports that dizziness, including feeling light-headed or faint when standing up quickly (orthostatic hypotension), is a documented uncommon side effect. If experienced, patients should review their symptoms with their treating physician.

Q: What is the typical age range of people who are prescribed Sulpirida?

According to regulatory documentation, the medicine is generally not recommended for use in children under 14 years of age due to insufficient data. Specific dosing guidelines are established for general adult populations, and caution with lower starting doses is advised for older adults.

Q: Does Sulpirida have an effect on blood pressure?

Yes, regulatory documentation indicates an effect on blood pressure. Orthostatic hypotension, which is a drop in blood pressure when standing, is listed as an uncommon side effect. Hypertension (high blood pressure) is also noted in the safety profile, though its frequency is sometimes classified as unknown.

Q: Why is it important to have regular check-ups while taking Sulpirida?

Regulatory guidelines indicate that regular monitoring is required because the medicine carries risks that necessitate careful observation, as noted in official warnings. This includes screening for potential changes in heart rhythm (QT interval prolongation), certain blood disorders like leukopenia, and the possibility of high prolactin levels.

Q: How should Sulpirida be taken for it to work best?

Official administration instructions detail that oral forms, such as tablets or capsules, are typically to be swallowed whole with water. It is generally administered in two divided doses per day. The patient's exact dose and timing schedule are determined and adjusted by the prescribing specialist based on individual response.

Q: How does a doctor decide who can use Sulpirida?

A doctor relies on official eligibility criteria, which define both contraindications and required caution. They ensure the patient does not have a condition that absolutely prohibits use, such as a prolactin-dependent tumor. The doctor also assesses risk factors—like heart rhythm concerns or renal impairment—that necessitate particular caution and close monitoring during treatment.

Q: Can I use Sulpirida if I have a history of heart problems?

Official safety warnings indicate the need for caution in patients with heart conditions, particularly those that affect heart rhythm. The medicine is contraindicated in combination with other agents that slow the heart rate or prolong the QT interval (a measure of heart rhythm).

Q: Is it normal for a doctor to start with a very low amount of Sulpirida?

Treatment protocols generally recommend that the prescriber utilize a cautious approach when initiating Sulpirida. This is explicitly stated in the documentation for older adults, where the initial dose is started low and gradually increased. The exact starting amount for the general adult population is determined by the specialist.

Q: How quickly do the effects of Sulpirida usually start to become noticeable?

Pharmacokinetic data from official sources indicates that the highest concentration of the drug in the blood is reached approximately 3 to 6 hours after an oral dose. For therapeutic effects, mood elevation may be observed after a few days, followed by the gradual resolution of the primary psychological symptoms.

Q: Is Sulpirida a controlled substance or addictive?

Sulpirida is classified by regulatory authorities as a prescription-only medicine (POM). It is not typically categorized as a controlled substance in the higher schedules used by major governmental drug regulatory bodies.

Q: Does Sulpirida affect the ability to drive or operate machinery?

Official warnings indicate that a person’s ability to drive or operate complex machinery may be impaired due to the risk of drowsiness or dizziness. This is a common warning for medicines that affect the central nervous system.

Q: Is there a maximum amount of time Sulpirida can be taken safely?

Official documentation does not specify a maximum duration for treatment. However, the risk of developing Tardive Dyskinesia, an involuntary movement disorder, is typically associated with prolonged administration. For patients on long-term therapy, regular monitoring is recommended due to this risk.

Q: Can Sulpirida cause dry mouth?

Yes, dry mouth is listed in official documentation as a possible adverse effect. The frequency with which this side effect occurs is sometimes classified as unknown.

Q: Is Sulpirida used for anxiety?

Anxiety is not listed as a primary approved indication in most major regulatory territories. However, studies have investigated the use of Sulpirida for anxiety-related conditions, and its approved use for Major Depressive Disorder may involve an effect on related symptoms of anxiety.

Q: What is the half-life of Sulpirida, and what does that mean for how often it’s taken?

Official pharmacokinetic information states that the half-life of Sulpirida in the body is approximately 8 hours. This property is part of the rationale for the typical administration schedule of two divided doses daily.

Q: Is it true that Sulpirida can be used as a short-term treatment?

Yes, the medicine can be used for short periods. The injectable solution form is often reserved for intramuscular administration in acute, severe settings for just a few days. After this acute period, the patient is typically transitioned to the oral formulation.

Q: Does Sulpirida affect appetite?

While changes in appetite are not explicitly listed in official adverse event sections, weight gain is noted as a common side effect of Sulpirida. This change in body mass may be associated with underlying effects on appetite and metabolism.

How should Sulpirida be stored and disposed of?

Storage Conditions and Disposal Instructions

The required storage conditions for Sulpirida vary by formulation. Certain tablet formulations mandate that the medicine do not store above 25 C, while others may state that the product does not require any special storage conditions. The regulatory shelf-life, which may be 3 to 5 years, is dependent on maintaining these environment rules.

  • Protection: The product must be kept in the original container and stored in a location that is out of the sight and reach of children.

  • Disposal: Any unused or expired Sulpirida must be disposed of in accordance with local requirements. The official label generally directs users to follow established pharmaceutical waste procedures and avoid discarding the product into household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sulpirida found in:

A-Z Index: